Hims & Hers stock plunges 16%. Its weight-loss drug strategy backfired.

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?

Hims & Hers last week announced a copycat version of the Wegovy pill that would cost $49 for the first month and $99 per month after on a five-month plan. That sent the stock surging last week, but shortly after the announcement, Novo Nordisk announced plans to sue Hims & Hers for patent infringement, which led the stock to give up those gains.

Hims & Hers Health: The Company Will Survive, But Investors Should Expect A 'Washout'

Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted. Click to read more on HIMS stock.
STAT

FDA warned a Hims & Hers compounder after finding bugs and failing to report a serious side effect

FDA inspectors found a live spider and dead cricket in a facility that was compounding weight loss drugs for Hims & Hers.